Cytek Biosciences Inc (CTKB)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -5,700 | -15,709 | 1,260 | 5,948 | 14,430 |
| Revenue | US$ in thousands | 200,453 | 193,015 | 164,036 | 127,950 | 92,839 |
| Pretax margin | -2.84% | -8.14% | 0.77% | 4.65% | 15.54% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-5,700K ÷ $200,453K
= -2.84%
Cytek Biosciences Inc's pretax margin has experienced fluctuations in the recent years. The pretax margin was at a healthy level of 15.54% on December 31, 2020. However, there was a significant decline in profitability as the pretax margin dropped to 4.65% by December 31, 2021. This trend continued with further decreases to 0.77% on December 31, 2022, and a notable negative pretax margin of -8.14% on December 31, 2023. Despite slight improvement, the pretax margin remained negative at -2.84% on December 31, 2024. These declining pretax margins indicate challenges in maintaining profitability and operational efficiency for Cytek Biosciences Inc.
Peer comparison
Dec 31, 2024